Assessing Glycemic Control in Maintenance Hemodialysis Patients With Type 2 Diabetes by Kazempour Ardebili, S et al.
Assessing Glycemic Control in Maintenance
Hemodialysis Patients With Type 2
Diabetes
SARA KAZEMPOUR-ARDEBILI, MD1
VARUNIKA L. LECAMWASAM, MRCP2
THUSHARA DASSANYAKE, BSC2
ANDREW H. FRANKEL, MD, FRCP2
FREDERICK W.K. TAM, PHD, FRCP2
ANNE DORNHORST, DM, FRCP3
GARY FROST, PHD1
JEREMY J.O. TURNER, DPHIL, MRCP1
OBJECTIVE— Optimizing glycemic control in diabetic patients undergoing maintenance
hemodialysis requires accurate assessment. We hypothesize that 1) 48-h continuous glucose
monitoring (CGM) provides additional, clinically relevant, information to that provided by the
A1C measurement and 2) glycemic profiles differ significantly between day on and day off
dialysis.
RESEARCHDESIGNANDMETHODS— With the use of GlucoDay S, 48-h CGM was
performed in 19 type 2 diabetic subjects undergoing hemodialysis to capture consecutive 24-h
periods on and off dialysis. Energy intake was calculated using food diaries. A1C was assayed by
a high-performance liquid chromatography method.
RESULTS— CGM data were available for 17 subjects (13 male) with a mean (range) age of
61.5 years (42–79 years) and diabetes duration of 18.8 years (4–30 years). The 24-h CGM area
under the glucose curve and 24-h mean glucose values were significantly higher during the day
off dialysis than on dialysis (5,932.1 2,673.6 vs. 4,694 1,988.0 mmol  3 min1  l1, P
0.022, and 12.6  5.6 vs. 9.8  3.8 mmol/l, P  0.013, respectively), independent of energy
intake. Asymptomatic hypoglycemia occurred in 4 subjects, 3 within 24 h of dialysis, and the
glucose nadir in 14 subjects occurred within 24 h of dialysis.
CONCLUSIONS— Glucose values are significantly lower on dialysis days than on nondi-
alysis days despite similar energy intake. The risk of asymptomatic hypoglycemia was highest
within 24 h of dialysis. Physicians caring for patients undergoing hemodialysis need to be aware
of this phenomenon and consider enhanced glycemic monitoring after a hemodialysis session.
CGM provides glycemic information in addition to A1C, which is potentially relevant to clinical
management.
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D iabetic nephropathy is the leadingcause of end-stage renal failure(ESRF) (1), representing 30–45%
of the U.K. and U.S. (2) populations un-
dergoing long-term maintenance hemo-
dialysis. The patients typically are elderly
type 2 diabetic patients with established
micro- and macrovascular disease (3).
Hypoglycemia is common because of im-
paired renal gluconeogenesis, malnutri-
tion, and the increased half-life of insulin
and hypoglycemic agents (4). The annual
mortality among diabetic patients under-
going hemodialysis is high and is pre-
dominately due to cardiovascular disease
(CVD) (2).
Intensive glycemic management de-
lays progression of microvascular disease
(5– 8) and improves malnutrition (9);
however, large randomized controlled tri-
als show no mortality benefit in high-risk
groups with CVD (7,10). Hypoglycemic
events increase with intensive treatment
and in the presence of CVD can cause fatal
dysrhythmia (11). U.K. diabetes guide-
lines advise against intensive treatment
aimed to lower A1C levels 6.5% (12),
whereas American guidelines caution
against values 7% (13). No evidence-
based guidelines for the glycemic targets
for diabetic patients with ESRF undergo-
ing long-term maintenance hemodialysis
are available.
In patients without ESRF, the A1C
value is routinely used to assess long-term
glycemic control, and assays are standard-
ized to those used in the Diabetes Control
and Complications Trial (14). There is a
strong correlation between A1C values
and the weighted mean glucose values of
the preceding 2–3 months (14).
The validity of the A1C measurement
in patients with ESRF undergoing hemo-
dialysis depends on the methodology
(15). A number of factors may influence
the assay including altered red blood cell
(RBC) life span and metabolic and me-
chanical factors (16). Potential metabolic
factors are interference from carbamy-
lated hemoglobin formed in uremia and
acetylated hemoglobin formed from long-
term aspirin use (17).
A limitation of the A1C value in pa-
tients undergoing hemodialysis is that it is
not informative regarding glycemic con-
trol on the days on and off dialysis. In the
U.K., maintenance hemodialysis is typi-
cally given in a hospital setting three times
a week, with sessions lasting 4–51⁄2 h. The
CGM devices that measure glucose every
3 min using a biosensor and a subcutane-
ous microbore cannula are, in contrast,
ideally suited to examine the effect of di-
alysis on glucose profiles over a 48-h pe-
riod. Thus, in the present study we test
the hypotheses 1) that 48-h CGM pro-
vides additional, clinically relevant, infor-
mation to that provided by the A1C
measurement in patients undergoing he-
modialysis and 2) that 24-h glucose pro-
files are different on the day that includes
a dialysis session compared with those on
a day that does not.
RESEARCH DESIGN AND
METHODS— The study was ap-
proved by the Hammersmith Hospital Re-
search Ethics Committee, and written
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informed consent was obtained (Registra-
tion No. 2002/6260). Study objectives
were to compare glucose profiles from
days on and off dialysis using 48-h CGM
in type 2 diabetic patients, to examine the
association between self-reported food in-
take and CGM values, and to evaluate gly-
cemic assessment obtained using 48-h
CGM in type 2 diabetic patients undergo-
ing maintenance hemodialysis.
Nineteen (14 male) type 2 diabetic
subjects were recruited from the mainte-
nance hemodialysis program at Imperial
College Kidney and Transplant Institute
(ICKTI). Dialysis was performed against a
2 mmol/l glucose-containing dialysate
for 4–51⁄2 h during the morning, after-
noon, or early evening. Inclusion criteria
were a stable hemoglobin level, defined as
a10% change in hemoglobin value and
no blood transfusion in the preceding 3
months, a stable dose of erythropoietin,
and no hemoglobinopathy. A history of
CVD was established as documented
ischemic heart disease (history of myocar-
dial infarction, a revascularization proce-
dure, or angiographically proven
coronary disease), cerebrovascular dis-
ease (history of cerebrovascular accident
or transient ischemic attack), or periph-
eral vascular disease (history of amputa-
tion due to gangrene, a revascularization
procedure, or peripheral vascular disease
proven angiographically or by Doppler
ultrasonography).
Blood samples
Blood samples were taken at the start of
dialysis for measurement of A1C, hemo-
globin, albumin, and urea.
CGM
Day 1. Subjects attended ICKTI, and
before they started dialysis a GlucoDay
S CGM device from A.Menarini Diagnos-
tics (Florence, Italy) (18) was fitted and
placed in a pouch to be worn around the
waist. The CGM biosensor was calibrated
retrospectively using capillary blood
glucose testing as advised by the
manufacturer.
Day 3 (48 h later). Subjects attended
ICKTI, and before their dialysis session
the CGM device was removed. The data
were downloaded to a computer using
dedicated software (GlucoDay S Data Pre-
sentation Software).
Exclusion criteria
Exclusion criteria were prospectively de-
fined as type 1 diabetes, intercurrent ill-
ness, changes to medication regimen
during the monitoring period, or occur-
rence of prolonged hypoglycemia.
Patient diaries
On day 1, subjects were given a 48-h di-
ary to record the exact time and amount of
food, drink, and medications taken dur-
ing the entire CGM monitoring period,
together with any episodes of symptom-
atic hypoglycemia and all capillary blood
glucose results.
Laboratory analysis
A1C measurements were performed in
the hospital’s clinical biochemistry lab-
oratory using a Diabetes Control and
Complications Trial–aligned HA-8160
A1C autoanalyzer (A.Menarini Diag-
nostics). This analyzer is not subject to
interference by urea, as this reverse-
phase cation exchange high-perfor-
mance liquid chromatography (HPLC)
method provides good separation of
A1C from carbamylated hemoglobin
A1. Hemoglobin measurements were
performed in the hospital’s routine he-
matology laboratory using a XE2100
autoanalyzer (Sysmex, Kobe, Japan)
running a variation of the CyMet hemo-
globin absorptiometric method. Serum
urea and serum albumin tests were per-
formed on an Architect ci8200 mul-
tichannel analyzer (Abbott Diagnostics,
North Chicago, IL).
Table 1—Clinical details of 17 subjects whose CGM data were included in the final analysis
n
Age
(years) Sex
Duration of
diabetes
(years)
Urea
(mmol/l)
CVD
(yes/no)* Medication
Hb
(g/dl)
A1C
(%)
Time undergoing
dialysis (years)
Erythropoietin
dose
(g/week)
1 53 M 20 5.1 Yes Gliclazide, 40 mg b.i.d. 13.4 5.1 1.2 30
2 59 M 18 19.3 Yes Gliclazide, 80 mg q.d. 11.3 5.3 3.7 80
3 65 M 6 15.1 Yes Diet 12.9 6 1.3 15
4 72 M 16 22.3 Yes Gliclazide, 80 mg q.d. 9.9 6 3 100
5 63 M 20 23.0 Yes Humulin M3 (8 units b.i.d.) 14.6 6.4 3.6 30
6 52 M 18 28.2 Yes Gliclazide, 40 mg b.i.d. 15.1 6.5 3.7 30
7 65 M 24 14.0 Yes NovoRapid (10 units A.M.),
Glargine (35 units P.M.)
12.1 6.6 2.8 60
8 68 M 26 14.0 Yes NovoMix 30 (10 units b.i.d.) 10.9 5.6 7.7 30
9 65 M 30 17.9 Yes Mixtard 30 (10 units, 8 units) 12 6.7 5.4 10
10 67 M 18 24.0 Yes Gliclazide, 40 mg b.i.d. 13.1 6.7 10.2 60
11 58 F 9 17.0 No Mixtard 50 (23 units, 24 units) 9.3 7.4 0.5 80
12 53 M 13 26.7 Yes Gliclazide, 160 mg b.i.d. 11.7 7.9 2.7 40
13 79 M 22 21.9 Yes Mixtard 30 (18 units, 12 units) 14 8 6.8 20
14 42 M 26 16.0 Yes Mixtard 30 (18 units, 12 units) 13.4 8.5 3.9 15
15 65 F 30 13.2 Yes Mixtard 30 (6 units b.i.d.) 13.8 7.3 6.2 50
16 65 F 4 14.5 Yes Gliclazide, 160 mg b.i.d. 12.4 8.9 3.3 30
17 54 F 19 17.8 No NovoMix 30 (16 units, 10 units) 11.7 9.2 1.7 60
*Documented history of vascular disease defined as ischemic heart disease (history of myocardial infarction, revascularization procedure or angiographically proven
coronary disease), cerebrovascular disease (history of cerebrovascular accident or transient ischemia attack) or peripheral vascular disease (history of amputation due
to gangrene, revascularization procedure, or peripheral vascular disease proven angiographically or by Doppler ultrasonography). F, female; M, male.
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Assessment of glycemic control
The 48-h glucose profiles were quanti-
fied, using dedicated software (GlucoDay
S Data Presentation Software), as the area
under the 3-min glucose curve (AUC) and
the mean glucose value. The time periods
studied were the first 24-h period starting
the first hour of dialysis (day on dialysis)
and the 24-h period ending 1 h before the
next dialysis session (day off dialysis). The
6-h nocturnal periods from midnight to
6:00 A.M. for each of these 24-h periods
were also examined to determine the ef-
fect of dialysis. Hypoglycemia, defined as
a continuous glucose reading 2.5
mmol/l for30 min, was identified from
the CGM profiles. Subjects were ques-
tioned regarding symptoms of hypoglyce-
mia at the end of the CGM period.
Dietetic analysis
Completed food diaries were checked
during a dietary consultation with a reg-
istered dietitian. Food portions were ver-
ified using a pictorial food atlas (19).
Comparisons of dietary intake during the
24-h periods on and off dialysis were per-
formed by a data analyst blinded to the
study using the Dietplan6 software pack-
age (Forestfield Software). The daily en-
ergy requirement was calculated to be
30–35 kcal/kg ideal body weight (20).
Statistical analysis
The CGM data were exported into SPSS
software (version 14; SPSS for Windows;
LEAD Technologies) and tested for nor-
mality using the Shapiro-Wilk test.
All normally distributed data are ex-
pressed as means SD and nonnormally
distributed data are expressed as median
(range). All comparisons of the glycemic
profiles and dietary intake between days
on and off dialysis were analyzed using
paired Student’s t tests. Linear regression
analysis was used to assess the relation-
ship between laboratory A1C and weekly
erythropoietin dose, serum urea, and se-
rum albumin. The level of significance
was defined as P  0.05.
RESULTS— Nineteen (14 male) sub-
jects were recruited, and 2 were subse-
quently excluded, one because of
repeated hypoglycemia during both mon-
itoring periods and one because of CGM
technical failure. The age, duration of di-
abetes, and years of dialysis [mean  SD
(range)] of the 17 (13 male) subjects in-
cluded were 61.5  8.8 years (42–79
years), 18.8 7.6 years (4–30 years), and
4  2.6 years (0.5–10.2 years), respec-
tively. Previous CVD history, diabetes
medications, erythropoietin dose, A1C,
hemoglobin, and urea values are given in
Table 1.
A1C values
The A1C (mean  SD) was 6.9  1.2%
(range 5.1–9.2%), with seven subjects
having A1C 6.5% (Table 1). Results of
linear regression analysis among A1C and
erythropoietin dose, serum albumin, and
urea were not significant (r2  0.17, P
0.0995; r2 0.161, P 0.536; and r2
0.163, P  0.533, respectively).
Hemoglobin values
Mean  SD hemoglobin was 12.4  1.6
g/l (range 9.3–15.1 g/l).
Analysis of glycemic profiles
The 24-h AUC glucose values and mean
24-h CGM data were significantly higher
the day off dialysis than the day on dialy-
sis (5,932.1 2,673.6 vs. 4,694 1,988
mmol  3 min1  l1, P  0.022, and
12.6  5.6 vs. 9.8  3.8 mmol/l, P 
0.013, respectively) (Fig. 1). The differ-
ence in the 24-h mean glucose levels for
the day off dialysis to the day on dialysis
ranged from 2.1 to 10.4 mmol/l.
The AUC glucose profiles and the
mean glucose values for the 6-h nocturnal
period from midnight to 6:00 A.M. were
significantly higher for the second than
for the first night (1,541  834 vs.
1,137  529 mmol  3 min1  l1, P 
0.05, and 12.9  7.0 vs. 9.5  4.4
mmol/l, P  0.05, respectively), with a
median 6-h mean nocturnal glucose dif-
ference of 4.2 mmol/l (range 8.5 to
17.1 mmol/l) (Fig. 2).
Analysis of hypoglycemia
Four of the 17 subjects had CGM record-
ings of 2.5 mmol/l for 30 min; in 3
subjects, this recording occurred in the
Figure 1—CGM data for day on (day 1) and day off (day 2) dialysis, expressed as AUC glucose
(A) andmean glucose (B) for each 24-h period.Œ—Œ, data for individual subjects;f, mean SD
for each 24-h period.A: Mean SD area under the 3-min glucose curve for the whole study group
was 5,932.1  2,673.6 mmol  3 min1  l1 on the day off dialysis vs. 4,694  1,988 mmol  3
min1  l1 on the day on dialysis (P 0.022). B: Mean SD CGM glucose values for the whole
group were 12.6 5.6 mmol/l on the day off dialysis vs. 9.8 3.8 mmol/l on the day on dialysis
(P  0.013).
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first 24-h monitoring period. Examina-
tion of individual CGM profiles showed
that 14 of 17 subjects reached their glu-
cose nadir (range 1.38 –9.81 mmol/l)
within the first 24 h, with 10 of 17 having
their lowest reading within 12 h of start-
ing dialysis. No subject reported any epi-
sode of symptomatic hypoglycemia.
Analysis of the food diaries
Two subjects failed to complete their 48-h
food diaries (subjects 6 and 15). Analysis
of the 15 completed diaries showed no
significant difference between recorded
dietary intakes for the day on dialysis and
the day off dialysis (1,636  603 vs.
1,702  559 kcal, respectively, P 
0.596). There was no trend toward
greater food intake on either day, with 7
subjects recording a greater calorie intake
during the day on dialysis versus 8 during
the day off dialysis. The timing of the di-
alysis shift did not appear to influence the
energy intake (data not shown). The total
energy intake for each subject was signif-
icantly lower, both on dialysis days (mean
1,636 kcal/day) and off dialysis days
(mean 1,702 kcal/day), than the esti-
mated mean energy requirement (2,000
kcal/day) (P  0.01; data not shown).
Medications
No subject recorded a change in fre-
quency or dosing of medications, includ-
ing insulin, on the 2 days.
CONCLUSIONS— The need to bal-
ance glycemic targets to avoid hypoglyce-
mia with the risks of microvascular
disease from hyperglycemia requires ac-
curate glycemic assessment. This is espe-
cially so for diabetic patients undergoing
maintenance hemodialysis, who have a
high prevalence of microvascular and ma-
crovascular disease and an increased risk
of asymptomatic hypoglycemia during
hemodialysis (21). The use of continuous
subcutaneous glucose monitors is ideally
suited for diabetic patients undergoing
hemodialysis because, unlike A1C mea-
surements, they can examine short-term
glycemic changes around the time of di-
alysis and are unaffected by urea, RBC life
span, and RBC production.
The need to set the appropriate glyce-
mic targets for type 2 diabetic patients
with a high CVD risk was highlighted by
the Action to Control Cardiovascular Risk
in Diabetes (ACCORD) (7) and the Action
in Diabetes and Vascular Disease: Pre-
terax and Diamicron Modified Release
Controlled Evaluation (ADVANCE) (8)
randomized controlled trials. These stud-
ies recruited subjects at high risk of CVD,
and neither showed any CVD benefit
from targeting A1C levels 6.5 and 7%,
respectively. The ACCORD study actually
showed a small increase in overall mortal-
ity when A1C 6.5% was targeted. That
low A1C levels may not confer survival
benefit in ESRF was also suggested by a
1-year follow-up study of 23,000 Ameri-
can diabetic subjects (22). In contrast,
good glycemic control before dialysis
does appear to have some CVD benefit
(23). Thus, it may be necessary for A1C
targets originally based on low CVD risk
populations without chronic kidney dis-
ease to be reevaluated for diabetic patients
undergoing hemodialysis.
The A1C is a measure of the irrevers-
ible nonenzymatic glycation product of
one or both NH2-terminal valines of the
-hemoglobin chain. In ESRF, the A1C
assay can be affected by interference from
carbamylated hemoglobin formed from
urea-derived isocyanate that accumulates
in uremia (24). However, advances in re-
verse-phase cation exchange HPLC ana-
lyzers, as used in this study, allow for
greater hemoglobin peak separation (25).
Shortened RBC life span or increased
RBC production (16) can occur in ESRF,
and both can falsely lower A1C values by
reducing the RBC glycemic exposure
time. However, a study of 23 patients un-
dergoing hemodialysis who were receiv-
ing regular erythropoietin therapy and
had stable hemoglobin values concluded
that the ambient glucose concentration
rather than RBC life span was the major
determinant, as no correlation between
RBC life span and A1C measured by ei-
ther immunoassay or HPLC was shown
(26). Starting or increasing erythropoietin
treatment could, by increasing RBC pro-
Figure 2—Nocturnal CGM data for the 6-h period from midnight to 6:00 A.M. for day on (night
1) and day off (night 2) dialysis, expressed as AUC glucose (A) andmean glucose (B).Œ—Œ, data
for individual subjects; f, mean SD for each 24-h period. A: Mean SD area under the 3-min
glucose curve for the whole study group was 1,541 834 mmol  3 min1  l1 for the night of the
day off dialysis (night 2) vs. 1,137 529 mmol  3 min1  l1 for the night of the day on dialysis
(night 1) (P  0.05). B: Mean  SD CGM glucose values for the whole group were 12.9  7.0
mmol/l on night 2 vs. 9.5 4.4 mmol/l on night 1.
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duction, falsely lower A1C values by in-
creasing the proportion of younger RBCs
and thereby reducing glucose exposure
time. In the present study, all subjects had
stable hemoglobin values and their eryth-
ropoietin doses had remained constant
over the preceding 3 months.
Furthermore, the A1C value may be
less informative in the type 2 diabetic
population undergoing maintenance he-
modialysis and may be less easily trans-
lated into mean glycemic values than in
other populations. The A1C Derived Av-
erage Glucose Study Group (ADAG) in-
vestigators recently reported (27) that
A1C levels can be converted to average
glucose levels in type 2 diabetic patients.
However, patients with chronic kidney
disease were excluded from this study,
and it is possible that the metabolic fluc-
tuations seen with hemodialysis may
weaken the relationship between A1C
and average glucose. CGM is one alterna-
tive to A1C for assessing glycemia.
The present study showed that over a
2-day period the GlucoDay S CGM device
recorded significantly higher glucose pro-
files on the day off dialysis than the day on
dialysis. The CGM glucose values during
the first 24-h monitoring period (day on
dialysis), including the 6-h nocturnal pe-
riod, were significantly less than those for
the second 24-h monitoring period. Dur-
ing the hours of midnight to 6.00 A.M., the
only common time all subjects were rest-
ing and not eating, the magnitude of this
difference ranged from 8.5 to 17.1
mmol/l, with a median difference of 4.2
mmol/l. These differences in glucose pro-
files were not explained by the difference
in 24-h energy intake, changes in medi-
cation, or dialysis shift. However, there
are potential limitations regarding the ac-
curacy of the food diaries, as data were
collected over 48 h only and were self-
reported. The food data did highlight the
fact that all subjects were likely to be mal-
nourished because they consumed less
than their recommended intake.
The CGM data also showed that 4
subjects had hypoglycemia (2.5 mmol/l
over 30 min) and that this occurred
within 24 h of dialysis in three subjects.
The lowest glucose recording for 14 sub-
jects was within the first 24-h period, with
the majority being within 12 h of dialysis.
Thus, the results of our study suggest that
type 2 diabetic patients undergoing main-
tenance hemodialysis, who already have a
very high risk of cardiovascular morbidity
and mortality, may have an increased risk
of hypoglycemia in the 24-h period after a
dialysis session. Current renal practice in-
cludes assessment of glycemic control by
blood glucose measurements while the
patient is undergoing hemodialysis. How-
ever, physicians caring for these patients
need to be aware of this phenomenon and
consider enhanced monitoring for these
patients who may develop hypoglycemia
several hours after they have left the dial-
ysis unit.
The subjects in this study were typical
of the U.K. type 2 diabetic population
with a long duration of diabetes (18.8 
7.6 years) and high prevalence rates of
established vascular disease (15 of 17
subjects) who are undergoing hemodial-
ysis. Our preliminary study suggests that
CGM offers clinically useful data for such
a high-risk group. Larger studies on pop-
ulations undergoing hemodialysis will be
required to determine whether data from
CGM should be used for medication ad-
justments around dialysis days to opti-
mize glycemic control and avoid
hypoglycemia.
In summary, as glycemic targets be-
come redefined to avoid overaggressive
management in individuals with high
CVD risk, it is important that the mea-
surements of glycemic control in patients
undergoing hemodialysis are as informa-
tive as possible.
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